Healthcare
Karyopharm Therapeutics Inc.(KPTI)
Live Price
Offline$9.02
-4.04% today
1Y Change
+100.89%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $70.00M
- Revenue Growth
- +0.6%
- EPS Growth
- -90.5%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Karyopharm Therapeutics Inc. (KPTI) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $9.02 and up 100.9% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +0.6%, EPS growth of -90.5%, a dividend yield of 0.0%. What stands out right now is revenue +0.6%, EPS -90.5%, free cash flow +40.9% with operating margin -62.1% and ROIC -236.6%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines KPTI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+0.6% vs +7.6% peer median
Operating Margin
Below sector median
-62.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 14, 2026 with an EPS surprise of +14.5% and a revenue surprise of +11.7%.
The operating picture looks softer than before
Revenue is at +0.6% and EPS is at -90.5%, with operating margin around -62.1%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 10, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.9% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | +14.5% | -13.8% | -9.4% | +6.7% |
2026 Feb 12, 2026 | +1.3% | -4.0% | +8.2% | -12.2% |
2025 Nov 3, 2025 | -10.1% | -6.9% | -10.4% | -11.7% |
Benchmark Edge
KPTI vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KPTI
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KPTI Max Drawdown
-48.36%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KPTI and SPY.
Company Overview
Karyopharm Therapeutics Inc.
NASDAQ Global Select
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
- Leadership
- Richard A. Paulson
- IPO Date
- Nov 6, 2013
- Employees
- 279
- Street Address
- 85 Wells Avenue
- Mailing
- Newton, MA, 02459
- Region
- Newton, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 658 0600
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.5
- Price/Book
- โ
Growth
- Revenue
- +0.6%
- EPS
- -90.5%
- Free Cash Flow
- +40.9%
Profitability
- Gross Margin
- 95.9%
- Operating Margin
- -62.1%
- Net Margin
- -134.2%
- ROE
- 77.9%
- ROIC
- -236.6%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.12
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.